Chondroitin sulfate as a key molecule in the development of atherosclerosis and cancer progression.
Theocharis
A D
AD
Laboratory of Biochemistry, Department of Chemistry, University of Patras, 26500 Patras, Greece.
Tsolakis
I
I
Tzanakakis
G N
GN
Karamanos
Nikos K
NK
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001011:Aorta / Q000502:physiology; D050197:Atherosclerosis / Q000209:etiology*; D001696:Biomechanical Phenomena; D011508:Chondroitin Sulfate Proteoglycans / Q000737:chemistry / Q000502:physiology; D002809:Chondroitin Sulfates / Q000502:physiology* / Q000627:therapeutic use; D016207:Cytokines / Q000502:physiology; D018450:Disease Progression; D004815:Epidermal Growth Factor / Q000378:metabolism; D005109:Extracellular Matrix / Q000378:metabolism; D066257:Heparin-binding EGF-like Growth Factor; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins; D008077:Lipoproteins, LDL / Q000378:metabolism; D009369:Neoplasms / Q000209:etiology*; D015398:Signal Transduction; D053675:Versicans / Q000502:physiology
D000970:Antineoplastic Agents; D011508:Chondroitin Sulfate Proteoglycans; D016207:Cytokines; C587883:HBEGF protein, human; D066257:Heparin-binding EGF-like Growth Factor; D036341:Intercellular Signaling Peptides and Proteins; D008077:Lipoproteins, LDL; C099252:oxidized low density lipoprotein; D053675:Versicans; D004815:Epidermal Growth Factor; D002809:Chondroitin Sulfates